The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping
Open Access
- 17 October 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in NAR Cancer
- Vol. 4 (4) , zcac030
Abstract
Molecular signatures have been suggested as biomarkers to classify pancreatic ductal adenocarcinoma (PDAC) into two, three, four or five subtypes. Since the robustness of existing signatures is controversial, we performed a systematic evaluation of four established signatures for PDAC stratification across nine publicly available datasets. Clustering revealed inconsistency of subtypes across independent datasets and in some cases a different number of PDAC subgroups than in the original study, casting doubt on the actual number of existing subtypes. Next, we built sixteen classification models to investigate the ability of the signatures for tumor subtype prediction. The overall classification performance ranged from ∼35% to ∼90% accuracy, suggesting instability of the signatures. Notably, permuted subtypes and random gene sets achieved very similar performance. Cellular decomposition and functional pathway enrichment analysis revealed strong tissue-specificity of the predicted classes. Our study highlights severe limitations and inconsistencies that can be attributed to technical biases in sample preparation and tumor purity, suggesting that PDAC molecular signatures do not generalize across datasets. How stromal heterogeneity and immune compartment interplay in the diverging development of PDAC is still unclear. Therefore, a more mechanistic or a cross-platform multi-omic approach seems necessary to extract more robust and clinically exploitable insights.Keywords
All Related Versions
Funding Information
- European Union's Horizon 2020 (777111)
- DFG (329628492, SFB1321, S02)
- German Federal Ministry of Education and Research
This publication has 59 references indexed in Scilit:
- Inflammatory networks and immune surveillance of pancreatic carcinomaCurrent Opinion in Immunology, 2013
- The Pancreas Cancer MicroenvironmentClinical Cancer Research, 2012
- Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer OutcomePLOS Computational Biology, 2011
- Somatic variation and cancer: therapies lost in the mixHuman Genetics, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapyNature Medicine, 2011
- Strictly Standardized Mean Difference, Standardized Mean Difference and Classicalt-test for the Comparison of Two GroupsStatistics in Biopharmaceutical Research, 2010
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005
- PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetesNature Genetics, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001